PD11-04 THE LIMITED UTILITY OF PROSTATE HEALTH INDEX IN AFRICAN AMERICAN MEN WITH A PSA 4-10

Abstract

You have accessJournal of UrologyCME1 May 2022PD11-04 THE LIMITED UTILITY OF PROSTATE HEALTH INDEX IN AFRICAN AMERICAN MEN WITH A PSA 4-10 Kostantinos Morris, Judd Moul, and Srinath Kotamarti Kostantinos MorrisKostantinos Morris More articles by this author , Judd MoulJudd Moul More articles by this author , and Srinath KotamartiSrinath Kotamarti More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002537.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Prostate Health Index (PHI) is a blood test approved for men being evaluated for prostate cancer (PCa) with a prostate specific antigen (PSA) in the “gray zone” of 4-10 ng/ml. As such, in the largest examination of PHI in African American (AA) men, we sought to assess PHI utility in the pre-biopsy work-up of this demographic, who notably were minimally represented in the original validation studies. METHODS: AA men in the Duke Health System with a PSA of 4-10 ng/mL, a PHI score, and subsequent prostate biopsy between 2016-2020 were identified. Established PHI cutoffs were utilized to stratify patients (Table 1). Multivariable logistical regressions were performed to assess possible predictors of cancer detection with the lowest PHI cutoff serving as reference. Clinically significant cancer (CSC) was defined as Gleason ≥7. RESULTS: A total of 1,131 AA men underwent PHI testing, and 236 met final inclusion criteria. Average age was 61.2 years. Mean PSA and PHI for the entire cohort were 6.5 ng/ml (SD 1.7) and 48.5 (SD 21.6), respectively. Detection rate at biopsy was 64.0% (n=151) for any PCa, ranging from 48.0% for PHI 0-26.9 to 84.1% for PHI ≥55 (Table 1). For CSC, overall detection rate was 44.5% (n=105), ranging from 24.0% for PHI 0-26.9 to 66.7% for PHI ≥55 (Table 1). On multivariable analysis, PHI ≥55 cutoff was the only PHI category associated with identification of all PCa (OR 5.66, p <0.01) and CSC (OR 6.15, p <0.01) (Table 2). CONCLUSIONS: Two-thirds of patients in the highest PHI category (≥ 55) were found to have CSC. This cutoff was the only stratification significantly associated with PCa detection. However, alarmingly, all established PHI cutoffs featured high rates of PCa and CSC. While elevated PHI in AA men with equivocal PSA should be regarded with heightened suspicion, our findings also highlight the difficulty in identifying patients at low risk who may benefit from a less fastidious approach. Likely, the current established stratification for PHI needs to be re-evaluated for the high-risk cohort of AA men. Source of Funding: None © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e190 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Kostantinos Morris More articles by this author Judd Moul More articles by this author Srinath Kotamarti More articles by this author Expand All Advertisement PDF DownloadLoading ...